Heparin And Alteplase: Why Not Combine For Stroke?

Heparin is not used with alteplase in stroke patients because of the risk of intracranial haemorrhage. Alteplase is a thrombolytic agent used to treat acute ischaemic stroke, and while it is considered safe and effective, it does have side effects. One of the most common complications is intracerebral haemorrhage, which is associated with an increased risk of mortality. As such, the combination of alteplase and heparin is not recommended for the treatment of acute ischaemic stroke.

Alteplase is not recommended for acute ischaemic stroke patients with intracranial haemorrhage

Alteplase is a thrombolytic agent that is used to treat acute ischaemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters. It is not recommended for acute ischaemic stroke patients with intracranial haemorrhage because it increases the risk of intracerebral haemorrhage. The risk of intracerebral haemorrhage is higher in patients with more severe strokes.

Alteplase is a fibrinolytic agent that converts plasminogen to the proteolytic enzyme plasmin, which lyses fibrin and fibrinogen. It is administered intravenously at a concentration of 1 mg/mL for the treatment of acute ischaemic stroke. The recommended dose is 0.9 mg/kg, with a maximum total dose of 90 mg. It should be administered as soon as possible and within 4.5 hours of symptom onset.

Intracranial haemorrhage is the most feared complication of intravenous thrombolytic therapy in acute ischaemic stroke. The risk of intracerebral haemorrhage varies depending on patient population and definition, but generally ranges from 2% to 7%. The risk is likely related to the dose of alteplase used, with higher rates noted at doses above 0.9 mg/kg.

The use of alteplase in acute ischaemic stroke patients with intracranial haemorrhage is limited by the risk of symptomatic intracranial haemorrhage (sICH). The risk of sICH is greater with alteplase compared to placebo for several definitions of sICH: ECASS III (6.8% vs 1.3%), SITS-MOST (3.7% vs 0.6%), and fatal haemorrhage (2.7% vs 0.4%). The risk of sICH is also likely to be related to the dose of alteplase used, with higher rates noted at doses above 0.9 mg/kg.

The development of post-thrombolytic haemorrhagic transformation requires multiple and interconnected pathological processes, including ischemic injury, coagulopathy, disruption of the blood-brain barrier, and reperfusion injury. The breakdown of the blood-brain barrier is a critical component in the development of haemorrhagic transformation.

The natural history of patients with sICH, particularly the PH-2 radiological subtype, is very poor, with a mortality rate of around 50%. The relationship between other radiological subtypes of haemorrhage and outcome is less clear.

Alteplase is not recommended for acute ischaemic stroke patients with subarachnoid haemorrhage

Alteplase is a thrombolytic agent that is used to treat acute ischaemic stroke. It is not recommended for patients with subarachnoid haemorrhage, as it can increase the risk of intracranial haemorrhage.

Alteplase is a fibrinolytic agent, also known as tissue plasminogen activator (tPA). It is administered intravenously and improves outcomes for selected patients with acute ischaemic stroke when given within 4.5 hours of the onset of symptoms. However, its use is limited by the risk of haemorrhagic complications, particularly symptomatic intracranial haemorrhage (sICH).

The risk of sICH varies depending on the patient population and the definition of sICH used, but it generally ranges from 2% to 7%. The risk is likely to be related to the dose of alteplase used, with higher rates noted at doses greater than 0.9 mg/kg.

The use of alteplase in patients with subarachnoid haemorrhage is contraindicated because it can increase the risk of intracranial haemorrhage. Alteplase converts plasminogen to the proteolytic enzyme plasmin, which lyses fibrin and fibrinogen. This can lead to a consumptive coagulopathy, causing a reduction in fibrinogen levels and prolongation of prothrombin and partial thromboplastin times. This coagulopathy has been associated with an increased risk of sICH.

Therefore, alteplase is not recommended for acute ischaemic stroke patients with subarachnoid haemorrhage due to the increased risk of intracranial haemorrhage.

Alteplase is not recommended for acute ischaemic stroke patients with a stroke within the last three months

Alteplase is a thrombolytic agent that is used to treat acute ischaemic stroke. It is recommended that patients who have had a stroke within the last three months should not be treated with alteplase. This is because the risk of bleeding is highest in patients with a recent history of intracranial haemorrhage.

Alteplase is a fibrinolytic agent, also referred to as tissue plasminogen activator (tPA). It is administered intravenously at a concentration of 1 mg/ml and is cleared primarily by the liver. The recommended dose for acute ischaemic stroke is 0.9 mg/kg, with a maximum total dose of 90 mg. Ten per cent of the total dose is administered as an intravenous bolus over one minute, and the remainder is infused over 60 minutes. Administration should take place as soon as possible and within 4.5 hours of symptom onset.

The NINDS trial, a randomised trial of IV alteplase versus placebo in patients with acute ischaemic stroke treated within three hours of symptom onset, found that alteplase improved functional outcomes at three months compared to placebo. However, alteplase was associated with a higher incidence of symptomatic intracranial haemorrhage than placebo.

The ECASS trial found that alteplase administered between 3 and 4.5 hours after the onset of acute ischaemic stroke symptoms resulted in a lower incidence of disability at three months compared to placebo. However, alteplase was again associated with a higher incidence of symptomatic intracranial haemorrhage.

In a retrospective cohort study of patients with acute ischaemic stroke who underwent alteplase-induced thrombolysis, six out of 23 patients (26%) experienced complications. Four patients (17%) had intracerebral haemorrhage, one patient (4%) developed orolingual angioedema, and one patient (4%) had a haematoma on their right arm. After treatment with alteplase, two patients (33%) in the study group died due to intracerebral haemorrhage, and one patient (17%) died due to aspiration pneumonia.

Overall, the use of alteplase in acute ischaemic stroke carries a risk of intracranial haemorrhage, particularly in patients with a recent history of stroke. Therefore, it is not recommended for patients who have had a stroke within the last three months.

Alteplase is not recommended for acute ischaemic stroke patients with intracranial or intraspinal surgery within the last three months

Alteplase is a thrombolytic agent that is used to treat acute ischaemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters. It is manufactured using recombinant DNA technology.

When treating acute ischaemic stroke, it is vital to identify eligible patients. Alteplase is not recommended for patients who have had intracranial or intraspinal surgery within the last three months, as the risk of bleeding is greater than the potential benefit. Other contraindications include current intracranial haemorrhage, subarachnoid haemorrhage, active internal bleeding, serious head trauma within the last three months, and the presence of intracranial conditions that may increase the risk of bleeding.

Patients should be carefully monitored during and after Alteplase administration, especially in the first 24 hours. It is important to check for signs of intracranial haemorrhage, bleeding, and hypersensitivity reactions.

Alteplase is not recommended for acute ischaemic stroke patients with serious head trauma within the last three months

Alteplase is a thrombolytic agent that is FDA-approved for use in acute ischaemic stroke. It is also known as tissue plasminogen activator (tPA) and works by converting plasminogen to the proteolytic enzyme plasmin, which lyses fibrin and fibrinogen.

The recommended dose for acute ischaemic stroke is 0.9 mg/kg, with a maximum total dose of 90 mg. Ten per cent of the total dose is administered as an intravenous (IV) bolus over one minute, with the remainder infused over 60 minutes. Administration should take place as soon as possible and within 4.5 hours of symptom onset.

Alteplase is contraindicated in patients with a history of intracranial haemorrhage, recent previous stroke, or serious head trauma within the last three months. Other contraindications include intracranial or intraspinal surgery within the last three months, intracranial neoplasms, arteriovenous malformations, or aneurysms, and conditions that increase the risk of bleeding.

The use of alteplase in acute ischaemic stroke has been associated with an increased risk of intracranial haemorrhage, particularly when administered more than three hours after stroke onset. However, it has been shown to improve clinical outcomes and reduce long-term death or dependence.

The British Heart Foundation states that the outcome of thrombolysis is better if given at one hour post-stroke than at three hours, and there may be a small benefit when administered between three and five hours post-stroke.

NICE (National Institute for Health and Care Excellence) has recommended alteplase for the treatment of acute ischaemic stroke when used by physicians trained and experienced in managing acute stroke. They also state that alteplase should only be used within 4.5 hours of symptom onset and when intracranial haemorrhage has been excluded by appropriate imaging techniques.

Frequently asked questions